Off-Label Promotion with Truthful Information

FDA remains a mysterious in its approach to off-label advertising and promotion. The development of a reasonable and coherent regulatory program seems beyond the FDA’s capacity. What seemed to work in the past does not keep pace with a person’s right to know. That approach runs counter to the FDA’s mantra of “transparency.” Breaking the ice is your job, otherwise, the FDA will freeze you in place. FDA’s regulation of off-label promotion and advertising has kept changing, especially so in the past year.

What FDA says is not acceptable to federal courts. Recent litigation opens the door for new sales and marketing possibilities, but you must use intelligent caution. Otherwise, the FDA may still pounce on you. That’s fine if you want to be the next test case in court. You need to be careful!

Attend this session to better understand FDA’s changes and rethinking in its approach to off-label promotion and advertising.

Areas Covered in the Session :

  • Identify legal criteria that the federal judiciary uses to push back the FDA
  • Learn how FDA is rethinking its approach and how not to be fooled by it
  • Consider how will the new FDA commissioner may affect FDA’s policy on off-label promotion and advertising
  • FDA’s legal goals
  • FDA’s growing legal failures
  • Policy development, tactics and inside hurdles under the Trump administration
  • Practical approaches for sales and marketing staff
  • Social media traps
Who Should Attend:

  • Regulatory Affairs Departments
  • Product Development Managers
  • Compliance Departments
  • Marketing Departments
  • FDA Consultants
  • In-house Legal Counsel


Casper E. Uldriks

Casper (Cap) Uldriks brings over 32 years of experience from the FDA. He specialized in the FDA’s medical device program as a field investigator, served as a senior manager in the Office of Compliance and as an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. He is recognized as an exceptional and energetic speaker. His comments are candid, straightforward and of practical value. He understands how FDA thinks, operates and where it is headed. Cap is the President of Encore Insight LLC, a consulting and training service for FDA law and operations.

  Go PRIME   🛈 $ 240 SELECT
  Personal Plan 🛈 $ 3000 SELECT
  Business Plan 🛈 $ 9000 SELECT

  • Login Information with Password to join the session, 24 hours prior to the webinar
  • Presentation Handout in .pdf format
  • Presentation from the Speaker
  • Feedback form
  • Certificate of Attendance
  • Recording access Information with Password to view the webinar, will be sent 24 hours after the completion of the Live webinar.
  • Presentation Handout in .pdf format
  • Certificate of Attendance